Bausch Health Companies Inc. (BHC)
NYQ · Healthcare · Drug Manufacturers - Specialty & Generic
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Bausch Health Companies Inc.
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 2.5B | 2.7B | 2.8B | 2.5B |
| Gross Profit | 1.8B | 1.9B | 2.0B | 1.8B |
| Operating Income | 457.0M | 636.0M | 829.0M | 521.0M |
| Net Income | 148.0M | 179.0M | -112.0M | -1.4B |
| Diluted EPS | $0.40 | $0.48 | $-0.30 | $-3.82 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 8.1B | 8.8B | 9.6B | 10.3B |
| Gross Profit | 5.8B | 6.2B | 6.8B | 7.3B |
| Operating Income | 1.4B | 1.6B | 1.9B | 2.2B |
| Net Income | -225.0M | -592.0M | -46.0M | 157.0M |
| Diluted EPS | $-0.62 | $-1.62 | $-0.13 | $0.42 |